Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

• Research on breast, colorectal, head and neck, and testicular cancers
• Novel downregulation of WNK1 and Wnt signaling

KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.

Titled Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10, a copy of the University of Calgary’s journal article is available here: https://www.mdpi.com/2072-6694/16/8/1520.

This work has been part of research conducted by Aru Narendran, M.D., Ph.D., professor in the departments of Pediatrics, Oncology, and Biochemistry & Molecular Biology, and members of the Narendran Lab at the University of Calgary’s Cumming School of Medicine in Calgary, Alberta, Canada.

The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors. The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling. In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.

Dominic Rodrigues, the Company’s President and Vice Chairman of its Board of Directors stated, “Provectus is focused on initiating an FDA-cleared, lead clinical development program for intratumoral cancer immunotherapy PV-10 to treat hepatic metastatic pancreatic cancer, and pursuing a path to an initial drug approval for PV-10. The Company previously demonstrated its systemic response and systemic immune signaling and activation in clinical settings for metastatic liver cancers.”

Mr. Rodrigues added, “Building on PV-10’s clinical safety, efficacy, and immunotherapeutic profile, the Narendran Lab’s preclinical data suggest that Provectus’s pharmaceutical-grade rose bengal delivered by oral administration may have the potential to treat a larger pool of solid tumor cancers.”

About Provectus

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium.